AavantiBio, Aldevron partner on gene therapy

By The Science Advisory Board staff writers

Aldevron made a deal to supply plasmid DNA that will enable AavantiBio to advance its gene therapies for rare genetic diseases.

Aldevron will supply plasmids to AavantiBio's planned vector core and contract development manufacturing organization partners. Also, the partnership includes materials for proof-of-concept and good lab practices (GLP) toxicology studies for future programs.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?